Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Sees Large Growth in Short Interest

Key Points

• Swedish Orphan Biovitrum saw a significant 52.4% increase in short interest, rising from 178,300 shares to 271,800 shares in August.
• The company reported $0.24 earnings per share (EPS) for the last quarter, exceeding analysts' estimates by $0.06 and generating revenue of $649.61 million.
• With a market capitalization of $10.39 billion, Swedish Orphan Biovitrum has a P/E ratio of 24.52 and a low debt-to-equity ratio of 0.22, indicating strong financial health.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) was the recipient of a large increase in short interest during the month of August. As of August 15th, there was short interest totaling 271,800 shares, an increase of 52.4% from the July 31st total of 178,300 shares. Based on an average daily volume of 100 shares, the short-interest ratio is currently 2,718.0 days. Based on an average daily volume of 100 shares, the short-interest ratio is currently 2,718.0 days.

Swedish Orphan Biovitrum Stock Performance

Shares of BIOVF remained flat at $29.18 during mid-day trading on Friday. The stock has a market capitalization of $10.39 billion, a price-to-earnings ratio of 24.52 and a beta of 0.45. The company has a quick ratio of 0.66, a current ratio of 1.00 and a debt-to-equity ratio of 0.22. The firm's 50 day simple moving average is $29.66 and its 200 day simple moving average is $29.48. Swedish Orphan Biovitrum has a 1 year low of $25.80 and a 1 year high of $32.25.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.06. Swedish Orphan Biovitrum had a net margin of 16.05% and a return on equity of 11.67%. The company had revenue of $649.61 million during the quarter, compared to analyst estimates of $644.68 million.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.